PREVIOUS
✖
CIPREMI
June 25 , 2020
1489 days
830
0
- The Union Health Ministry added ‘Remdesivir’ only for restricted emergency use for Covid 19.
- Hetero and Cipla Pharmaceuticals were granted approval by the Drug Controller General of India for the production and marketing of this antiviral drug Remdesivir.
- Under the brand name ‘Covifor’, the Hyderabad based Hetero Pharmaceuticals’ generic version of Remdesivir will be marketed in India.
- The United States-based biopharmaceutical company, Gilead Sciences is the developer of this drug.
- Cipla was granted the voluntary non-exclusive by Gilead Science for manufacturing and marketing of the drug in India under generic drug name ‘CIPREMI’.
- Covifor is the second such drug to enter the Indian market after Fabiflu by Glenmark.
- Japan was the first country to approve Remdesivir drug as a treatment for COVID-19.
- United Kingdom, Singapore, and Japan are the only countries where the drug has been approved.
Leave a Reply
Your Comment is awaiting moderation.